Breaking News Instant updates and real-time market news.

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, GILD

Gilead

$66.91

-0.24 (-0.36%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30

Alpine Immune Sciences reports notice of termination of license pact with Kite

In a regulatory filing earlier, Alpine Immune Sciences (ALPN) disclosed that on May 20, Kite Pharma, a Gilead (GILD) company, provided the company notice of termination of the license and research agreement, by and between a wholly-owned subsidiary of the company and Kite, dated as of October 26, 2015, as amended. Kite terminated the agreement following the expiration of the research term, as defined in the agreement. Upon termination, the confidentiality and indemnity obligations of the parties will survive and the licenses granted to Kite under the agreement will terminate. Pursuant to the terms of the agreement, the termination will be effective on June 20, thirty days after the effectiveness of Kite's notice, Alpine stated.

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

GILD

Gilead

$66.91

-0.24 (-0.36%)

  • 31

    May

  • 13

    Jun

ALPN Alpine Immune Sciences
$5.27

-0.34 (-6.06%)

05/15/19
PIPR
05/15/19
NO CHANGE
Target $11
PIPR
Overweight
Piper sees broad partnership potential for Alpine after Adaptimmune deal
After Alpine Immune Sciences (ALPN) announced a partnership with Adaptimmune (ADAP) to incorporate its novel Transmembrane and Secreted Immunomodulatory Proteins, or TIPs and SIPs, into CAR-T cells, Piper Jaffray analyst Edward Tenthoff said he sees Alpine having broad potential to partner its TIPs and SIPs for next generation cellular therapies. The analyst, who noted that Alpine is also advancing a platform of novel variant Ig domains, or "vIgDs," to augment T-cell activation, keeps an Overweight rating and $11 price target on Alpine shares.
01/22/19
PIPR
01/22/19
NO CHANGE
Target $11
PIPR
Overweight
Alpine Immune Sciences target lowered to $11 placement dilution at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Alpine Immune Sciences to $11 from $12 to reflect dilition from the company's recent private placement. Alpine recently issued 4.7 million units at $5.37 comprised of one share and 0.39 warrants with a $12.74 strike price raising gross proceeds of $25.3M, Tenthoff tells investors in a research note. The analyst estimates Alpine now holds pro forma cash of $86M to advance its pipeline of proprietary variant Ig domains as novel immunotherapies. He reiterates an Overweight rating on the shares.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
11/11/18
PIPR
11/11/18
NO CHANGE
Target $12
PIPR
Overweight
Piper Jaffray bullish on Alpine after 'robust' ALPN-202 preclinical activity
Piper Jaffray analyst Edward Tenthoff notes that Alpine Immune Sciences presented two posters at SITC for immuno-oncology variable Immunoglobulin Domain candidates. The analyst points out that new preclinical data on ALPN-202, which co-engages PD-L1 and CTLA-4 to selectively stimulates CD28 on T-cells, demonstrated "robust" anti-tumor activity in vivo compared to single agent anti-PD-1 durvalumab. He believes SITC data indicated vIgDs unique co-engagement at the synpase generates superior anti-tumor activity, and says Alpine will file an IND on lead autoimmune vIgD ALPN-101 by year-end 2018 and could prove superior to Orencia with preclinical data at ASH. Tenthoff reiterates an Overweight rating and $12 price target on the shares.
GILD Gilead
$66.91

-0.24 (-0.36%)

05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."
05/22/19
SBSH
05/22/19
UPGRADE
SBSH
Buy
Gilead upgraded to Buy from Neutral at Citi
05/20/19
FBCO
05/20/19
INITIATION
Target $70
FBCO
Neutral
Gilead initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Gilead Sciences with a Neutral rating and $70 price target. The does not see "outsized growth" in the company's base HIV business that would drive significant upside to earnings projections. He admits, however, that a new strategic vision or acquisition could lead to multiplier expansion.
05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.

TODAY'S FREE FLY STORIES

LOGC

LogicBio Therapeutics

$12.55

0.41 (3.38%)

14:26
07/15/19
07/15
14:26
07/15/19
14:26
Conference/Events
LogicBio Therapeutics management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

QURE

uniQure

$68.66

-1.74 (-2.47%)

14:25
07/15/19
07/15
14:25
07/15/19
14:25
Options
uniQure call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 09

    Sep

AVGO

Broadcom

$290.65

5.26 (1.84%)

, SYMC

Symantec

$21.78

-3.78 (-14.79%)

14:21
07/15/19
07/15
14:21
07/15/19
14:21
Periodicals
Broadcom still keen to find solution as Symantec bid stalls over price, FT says »

Broadcom's (AVGO)…

AVGO

Broadcom

$290.65

5.26 (1.84%)

SYMC

Symantec

$21.78

-3.78 (-14.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/15/19
07/15
14:17
07/15/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/15/19
07/15
14:16
07/15/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$26.49

-0.32 (-1.19%)

14:15
07/15/19
07/15
14:15
07/15/19
14:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

14:15
07/15/19
07/15
14:15
07/15/19
14:15
General news
Fed funds futures are fractionally higher »

Fed funds futures are…

FB

Facebook

$203.96

-0.945 (-0.46%)

, BTC

Bitcoin

$0.00

(0.00%)

14:14
07/15/19
07/15
14:14
07/15/19
14:14
Hot Stocks
Mnuchin says Trump has cryptocurrency concerns, won't target a specific provider »

Asked about President…

FB

Facebook

$203.96

-0.945 (-0.46%)

BTC

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

C

Citi

$71.87

0.12 (0.17%)

14:11
07/15/19
07/15
14:11
07/15/19
14:11
Hot Stocks
Citi reports June credit loss rate 2.56% vs. 2.74% last month »

Reports June 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 13

    Aug

FB

Facebook

$203.77

-1.135 (-0.55%)

14:09
07/15/19
07/15
14:09
07/15/19
14:09
Hot Stocks
Breaking Hot Stocks news story on Facebook »

Mnuchin says Facebook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

FB

Facebook

$203.81

-1.095 (-0.53%)

, BTC

Bitcoin

$0.00

(0.00%)

14:07
07/15/19
07/15
14:07
07/15/19
14:07
Hot Stocks
Mnuchin says Treasury has 'serious concerns' about Facebook's Libra, bitcoin »

Treasury Secretary Steven…

FB

Facebook

$203.81

-1.095 (-0.53%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

SCHW

Charles Schwab

$40.49

0.47 (1.17%)

14:05
07/15/19
07/15
14:05
07/15/19
14:05
Options
Charles Schwab call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Oct

CSGP

CoStar Group

$583.45

-3.56 (-0.61%)

14:05
07/15/19
07/15
14:05
07/15/19
14:05
Hot Stocks
CoStar Group signs agreement with Behar Group Realty »

CoStar Group is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 12

    Aug

  • 13

    Nov

HTGC

Hercules Capital

$12.96

-0.02 (-0.15%)

14:00
07/15/19
07/15
14:00
07/15/19
14:00
Hot Stocks
Hercules Capital reports separation agreement with Manuel Henriquez »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

GLPG

Galapagos

$170.88

25.21 (17.31%)

13:59
07/15/19
07/15
13:59
07/15/19
13:59
Downgrade
Galapagos rating change at Raymond James »

Galapagos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 09

    Sep

LVMUY

LVMH

$0.00

(0.00%)

13:52
07/15/19
07/15
13:52
07/15/19
13:52
Hot Stocks
LVMH announces partnership with Stella McCartney »

Stella McCartney and LVMH…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

SCHW

Charles Schwab

$40.49

0.47 (1.17%)

13:51
07/15/19
07/15
13:51
07/15/19
13:51
Recommendations
Charles Schwab analyst commentary  »

Wells says Schwab deal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Oct

AMC

AMC Entertainment

$9.45

(0.00%)

13:45
07/15/19
07/15
13:45
07/15/19
13:45
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

SPY

SPDR S&P 500 ETF Trust

$300.31

-0.37 (-0.12%)

, SPX

S&P 500

$0.00

(0.00%)

13:43
07/15/19
07/15
13:43
07/15/19
13:43
Periodicals
Trump ponders firing Commerce Secretary Wilbur Ross, NBC News says »

According to an earlier…

SPY

SPDR S&P 500 ETF Trust

$300.31

-0.37 (-0.12%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCO

The Medicines Co.

$36.65

-0.03 (-0.08%)

13:35
07/15/19
07/15
13:35
07/15/19
13:35
Options
Medicines Company put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTGN

Neon Therapeutics

$4.61

0.3 (6.96%)

13:30
07/15/19
07/15
13:30
07/15/19
13:30
Recommendations
Neon Therapeutics analyst commentary at Mizuho »

Neon Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

SYMC

Symantec

$21.73

-3.83 (-14.98%)

, AVGO

Broadcom

$289.18

3.79 (1.33%)

13:27
07/15/19
07/15
13:27
07/15/19
13:27
Periodicals
Broadcom was willing to pay up $28.25 per share for Symantec, Reuters reports »

Symantec (SYMC) walked…

SYMC

Symantec

$21.73

-3.83 (-14.98%)

AVGO

Broadcom

$289.18

3.79 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$25.55

1.25 (5.14%)

13:25
07/15/19
07/15
13:25
07/15/19
13:25
Options
Cara Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
07/15/19
07/15
13:25
07/15/19
13:25
Conference/Events
Stephens consumer/poultry & egg analysts hold analyst/industry conference call »

Analysts provide an…

A

Agilent

$69.90

-1.75 (-2.44%)

13:25
07/15/19
07/15
13:25
07/15/19
13:25
Conference/Events
The Brookings Institution to hold a conference »

8th annual Municipal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.